|

Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity

RECRUITINGN/ASponsored by National Cancer Institute, Egypt
Actively Recruiting
PhaseN/A
SponsorNational Cancer Institute, Egypt
Started2025-10-20
Est. completion2026-04-01
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07276867

Summary

The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age from 18 to 60 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status of II-III.
* Height between 150-185 cm.
* Body mass index between 18-35 kg/m².
* Scheduled for above-knee amputation due to lower limb sarcomas.

Exclusion Criteria:

* Allergy to any of the investigated drugs.
* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.
* Contraindications to spinal anesthesia.
* Pregnancy or lactation.
* Presence of psychiatric illness or chronic pain conditions.

Conditions9

Above Knee AmputationBupivacaineCancerDexmedetomidineFentanylIntrathecalLower ExtremitySarcomasSpinal Anesthesia

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.